11th Translational Research Conference: Myeloproliferative Neoplasms #ESHMPN2026

Conference Details

Date: 24 April 2026

Time: 08:30

Duration: 3 days

Location: Estoril, Portugal

Cost: € 300 - € 600

Organiser: ESH - European School of Haematology

Conference Website

Conference Description

ABOUT THE CONFERENCE:

ESH Translational Research Conferences focus on leading-edge basic, clinical and therapeutic research and future perspectives. The presentation of unpublished data is encouraged. Ample time is deliberately provided for in-depth scientific discussion and interaction.
Registered participants further benefit from a variety of opportunities for informal scientific interaction with the world’s leading experts in their field, including during small Meet the Expert sessions and Mentored Posters Walks.

New insights into the molecular pathogenesis, classification, and management of patients with Myeloproliferative Neoplasms (MPN) have arisen at increasing pace during the past years. This International Conference brings together scientists and clinicians to present and discuss new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.

SCIENTIFIC TOPICS:

• Somatic evolution and MPN;
• New approaches for targeting MPN;
• New causes and classification;
• Recent developments in blast phase MPN;
• Novel functional insights downstream of JAK/CALR/MPL;
• MPN management;
• Disease mechanisms in MPN;
• Aberrant cell populations in MPN;
• New frontiers in MPN, where is the field going?

THE PROGRAMME WILL INCLUDE:

• Plenary Sessions;
• Keynote Lectures;
• Panel Discussions;
• Simultaneous Meet the Expert Sessions;
• Mentored Poster Walks;
• Brief Oral Communications;
• Ample time for in-depth discussion.

LEARNING OBJECTIVES:

• Understand the newest discoveries on the molecular pathogenesis of MPN;
• Appreciate recent changes in treatment recommendations for MPN patients including the evolving landscape of approved therapies;
• Gain insight into ongoing clinical trials investigating novel agents for MPN treatment.